XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We operate as one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases. Segment profit or loss is measured as the net loss reported on our Consolidated Statements of Operations and Comprehensive Loss and net loss is used to monitor results. Our segment revenue consists of milestone payments, royalty payments, upfront license fees and transition services provided under our collaboration agreements, see Note 4. The measure of segment assets is reported on our Consolidated Balance Sheets as total assets.
The CODM is our Chief Executive Officer. The CODM manages the business activities on a consolidated basis in making decisions regarding resource allocation and performance assessment.
The following table is a summary of segment revenue, loss and our significant expenses (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Collaboration revenue$22,263 $10,971 $50,034 $18,150 
Operating expenses:
External R&D
Rosnilimab15,614 12,926 30,639 22,965 
ANB0333,925 2,982 7,729 5,645 
ANB1012,040 544 3,521 944 
ANB032108 7,584 3,644 12,451 
Imsidolimab(967)1,867 (1,156)6,363 
Preclinical and other unallocated costs4,456 4,693 8,388 8,037 
Total External R&D(1)
25,176 30,596 52,765 56,405 
Total Internal R&D(2)
12,648 11,401 26,239 22,634 
Total R&D37,824 41,997 79,004 79,039 
External G&A(3)
2,436 2,330 7,976 4,451 
Internal G&A(2)
8,173 6,965 16,763 17,182 
Total G&A10,609 9,295 24,739 21,633 
Total operating expenses48,433 51,292 103,743 100,672 
Loss from operations(26,170)(40,321)(53,709)(82,522)
Interest income3,654 4,623 8,067 9,207 
Non-cash interest expense(19,606)(10,953)(37,667)(17,270)
Other income (expense), net3,531 — 5,433 (2)
Total other expense, net
(12,421)(6,330)(24,167)(8,065)
Loss before income taxes(38,591)(46,651)(77,876)(90,587)
Provision for income taxes
(39)(9)(83)(9)
Segment net loss$(38,630)$(46,660)$(77,959)$(90,596)
(1)     External R&D consists of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, manufacturing, and allocated facility-related costs.
(2)     Internal R&D and G&A consist of salaries and wages, stock-based compensation, recruiting and other employee benefits.
(3)     External G&A consists of general and administrative expenses including transaction costs, legal services, insurance, professional fees for auditing, tax, and market research, and allocated facility-related costs not otherwise included in research and development expenses.